Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

Arcus Biosciences is a high-risk speculation with major upcoming catalysts, despite stock declines and Gilead's exit from the ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

Hulu announced that it is developing a series based on Margaret Atwood's 2019 novel "The Testaments," which is a follow-up to ...

The Wadesboro Police Department is mourning the loss of K-9 Blitz, who died during a traffic stop incident that escalated ...

Bruce Miller knew for a long time how he wanted to bring the story to a conclusion,' says EP Eric Tuchman. 'It's about June's ...

As the sixth and final season of The Handmaid’s Tale is nearing its premiere next week, production on its sequel series The ...

Welcome back to Gilead. “The Handmaid’s Tale” sequel series “The Testaments” has officially received a series order from Hulu ...